References
- Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdiek E, Fiueberj HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271: 698–702
- Udani PM. BCG vaccination in India and tuberculosis in children: newer facets. Indian J Pediatr 1994; 61: 451–62
- World Health Organization. BCG vaccine. WHO position paper. Wkly Epidemiol Rec 2004;79:27–38.
- Fine PEM, Carneiro IAM, Milstien JB, Clements CJ. Issues relating to the use of BCG immunization programmes–a discussion document. World Health Organization (WHO) document no. WHO/V&B/99.23. Geneva: WHO, 1999.
- Milstien JB, Gibson JJ. Quality control of BCG by WHO: a review of factors that may influence vaccine effectiveness and safety. Bull World Health Organ 1990; 68: 93–108
- Lotte A, Wasz-Hockert O, Poisson N, Engbaek H, Landmann H, Quast U, et al. Second IUATLD study on complications induced by intradermal BCG vaccination. Bull Int Union Tuberc Lung Dis 1988; 63: 47–59
- Talbot EA, Perkins MD, Silva SF, Frothingham R. Disseminated Bacille Calmette-Guerin disease after vaccination: case report and review. Clin Infect Dis 1997; 24: 1139–46
- Richter E, Weizenegger M, Rüsch-Gerdes S, Niemann S. Evaluation of genotype MTBC assay for differentiation of clinical Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2003; 41: 2672–5
- Lumb R, Shaw D. Mycobacterium bovis (BCG) vaccination: progressive disease in a patient asymptomatically infected with the human immunodeficiency virus. Med J Aust 1992; 156: 286–7
- Smith E, Thybo S, Bennedsen J. Infection with Mycobacterium bovis in a patient with AIDS: a late complication of BCG vaccination. Scand J Infect Dis 1992; 24: 109–10
- Hofstadler G, Schmitt K, Tulzer G, Binder L, Brandstetter B. BCG lymphadenitis in an HIV-infected child 9.5 y after vaccination. AIDS Patient Care STDS 1998; 12: 677–80
- Marks K, Amitai Y, Engelhard D, Kori M, Maayan S. Mycobacterium bovis lymphadenitis complicating BCG immunization in an infant with symptomatic HIV-1 infection. Isr J Med Sci 1993; 29: 381–2
- Puthanakit T, Oberdorfer P, Punjaisee S, Wannarit P, Sirisanthana T, Sirisanthana V. Immune reconstitution syndrome due to Bacillus Calmette-Guerin after initiation of antiretroviral therapy in children with HIV infection. Clin Infect Dis 2005; 41: 1049–52
- Sharp MJ, Mallon DF. Regional Bacillus Calmette-Guerin lymphadenitis after initiating antiretroviral therapy in an infant with human immunodeficiency virus type 1 infection. Pediatr Infect Dis 1998; 17: 660–2
- Armbruster C, Junker W, Vetter N, Jaksch G. Disseminated bacille Calmette-Guerin infection in an AIDS patient 30 years after BCG vaccination. J Infect Dis 1990; 162: 1216
- Hesseling AC, Schaaf HS, Hanekom WA, Beyers N, Cotton MF, Gie RP, et al. Danish Bacille Calmette-Guerin vaccine-induced disease in human immunodeficiency virus-infected children. Clin Infect Dis 2003; 37: 1226–33
- Archibald LK, Kazembe PN, Nwanyanwu O, Mwansambo C, Reller LB, Jarvis WR. Epidemiology of bloodstream infections in a Bacille Calmette-Guerin-vaccinated paediatric population in Malawi. J Infect Dis 2003; 188: 202–8
- Waddell RD, Lishimpi K, Von Reyn CF, Chintu C, Baboo KS, Kreiswirth B, et al. Dartmouth/UCLMS/UNZA Collaborative Study Group. Bacteraemia due to Mycobacterium tuberculosis or M. bovis, Bacille Calmette-Guerin (BCG) among HIV-positive children and adults in Zambia. AIDS 2001; 15: 55–60
- Wayne LG. Microbiology of tubercle bacilli. Am Rev Respir Dis 1982; 125: 31–41
- Talbot EA, Williams DL, Frothingham R. PCR identification of Mycobacterium bovis BCG. Journal of Clinical Microbiology 1997; 35: 566–9